Trade

Laurus Labs share price

Balanced risk
  • 26%Low risk
  • 26%Moderate risk
  • 26%Balanced risk
  • 26%High risk
  • 26%Extreme risk
  • 1,089.75(3.08%)
    January 14, 2026 15:25:44 PM IST
    • NSE
    • BSE
  • Vol : 2.41 M (NSE + BSE)
    Last 20 day avg : 1.60 M

Laurus Labs is trading 3.08% upper at Rs 1,089.75 as compared to its last closing price. Laurus Labs has been trading in the price range of 1,098.10 & 1,057.80. Laurus Labs has given -1.58% in this year & -3.37% in the last 5 days. Laurus Labs has TTM P/E ratio 66.36 as compared to the sector P/E of 22.78.There are 13 analysts who have initiated coverage on Laurus Labs. There are 2 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 194.97 Crores in its last quarter.Listed peers of Laurus Labs include Divi's Laboratories (-1.29%), Sun Pharmaceutical Industries (-1.69%), Torrent Pharmaceuticals (1.62%).The Mutual Fund holding in Laurus Labs was at 8.53% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Laurus Labs was at 26.17% in 30 Sep 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jan 15, 2026, 04:08 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.91
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.62
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.15
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -3.53
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
1,057.80
Highest
1,098.10
52 week range
Lowest
504.30
Highest
1,140.90
Laurus Labs Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Divi's Laboratories
Neutral
6,350.50-1.291,68,751.7478.6111.520.460.01
Sun Pharmaceutical Industries
Neutral
1,700.55-1.694,08,009.3036.245.770.920.50
Torrent Pharmaceuticals
Bullish
4,003.251.621,35,536.8867.3217.10.8317.62
Cipla
Bearish
1,434.60-0.901,15,882.9422.953.870.870.81
Dr Reddy's Laboratories
Bearish
1,187.70-0.2299,020.0918.633.140.632.34
Mutual Fund Ownership
View all
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 135.21
  • % of AUM 4.57
Tata Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 5.87
  • % of AUM 4.30
Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.04
  • % of AUM 4.28
Kotak Nifty Smallcap 50 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 4.71
  • % of AUM 3.63
Aditya Birla Sun Life Nifty Smallcap 50 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 8.38
  • % of AUM 3.63
Laurus Labs Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-01-23Quarterly Results
2025-10-23Quarterly Results & Interim Dividend
2025-07-25Quarterly Results
2025-04-24Audited Results & Interim Dividend
2025-01-24Quarterly Results
About the company Laurus Labs
  • IndustryBiotechnology & Drugs
  • ISININE947Q01028
  • BSE Code540222
  • NSE CodeLAURUSLABS
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.
  • Management Info
  • Satyanarayana ChavaChief Executive Officer, Executive Director
  • Venkata Ravi VantaramChief Financial Officer, Executive Director
  • V. Uma Maheswer RaoPresident Chemical R and D
  • Srinivasa SuryadevaraPresident - Manufacturing and Operations
  • Thomas VersoskyPresident - FDF, North America
  • Jyothi Basu AbbibeniExecutive Vice President - Chemical R and D
  • Narasimha ChavaExecutive Vice President - Human Resources
  • Rajaram IyerExecutive Vice President Portfolio Management
  • Martyn James PeckExecutive Vice President Business Development
  • Sita RamaiahExecutive Vice President - Finance
Laurus Labs Share Price FAQs

Laurus Labs is trading at 1089.75 as on Wed Jan 14 2026 09:55:44. This is 3.08% upper as compared to its previous closing price of 1057.20.

The market capitalization of Laurus Labs is 58830.87 Cr as on Wed Jan 14 2026 09:55:44.

The average broker rating on Laurus Labs is Hold. The breakup of analyst rating is given below -

  • 2 analysts have given a strong buy rating
  • 3 analysts have given a buy rating
  • 2 analysts have given a hold rating
  • 3 analysts have given a sell rating
  • 3 analysts have given a strong sell rating

The 52 wk high for Laurus Labs is 1140.90 whereas the 52 wk low is 504.30

Laurus Labs can be analyzed on the following key metrics -

  • TTM P/E: 66.36
  • Sector P/E: 22.78
  • Dividend Yield: 0.15%
  • D/E ratio: 0.46

Laurus Labs reported a net profit of 358.32 Cr in 2025.

The Mutual Fund Shareholding was 8.53% at the end of 30 Sep 2025.